However, several constraints of antibody-based therapy such as limited tumor penetration and antigen-mediated clearance with subsequently shortened response duration prompted the exploration of the CAR pathway for a more efficient CD30 targeting [89]. This evidence concerns the gene TNFRSF8 and neoplasm.